Indirect comparisons of brigatinib and alectinib for front-line ALK-positive non-small-cell lung cancer.
Loading...
Embargo End Date
ICR Authors
Authors
Reckamp, KL
Lin, HM
Cranmer, H
Wu, Y
Zhang, P
Walton, LJ
Kay, S
Cichewicz, A
Neupane, B
Fahrbach, K
Popat, S
Camidge, DR
Lin, HM
Cranmer, H
Wu, Y
Zhang, P
Walton, LJ
Kay, S
Cichewicz, A
Neupane, B
Fahrbach, K
Popat, S
Camidge, DR
Document Type
Journal Article
Date
2022-05-24
Date Accepted
2022-04-27
Abstract
Aim: To conduct an indirect treatment comparison (ITC) of the relative efficacy of brigatinib and alectinib for progression-free survival in people with tyrosine kinase inhibitor (TKI)-naive ALK-positive non-small-cell lung cancer (NSCLC). Methods: Final aggregate and patient-level data from the ALTA-1L trial comparing brigatinib to crizotinib and published aggregate data from ALEX (comparing alectinib to crizotinib) were contrasted using Bucher ITC and matching-adjusted indirect comparisons (MAICs). Results: No statistically significant differences were identified between brigatinib and alectinib in reducing the risk of disease progression overall and in patients with baseline central nervous system metastases. Conclusion: Brigatinib appeared similar to alectinib in reducing risk of disease progression for people with TKI-naive ALK-positive NSCLC.
Citation
Future Oncology, 2022, 18 (20), pp. 2499 - 2510
Source Title
Future Oncology
Publisher
FUTURE MEDICINE LTD
ISSN
1479-6694
eISSN
1744-8301
1744-8301
1744-8301